[Human serum albumin: gene-technological possibilities].
Gene technology will soon render it possible to make recombinant human serum albumin for clinical use, to produce albumins with altered biological half-lives and isoforms with such high and specific binding affinity that they may be used as antidotes. Mutants with increased affinity for different cell types can be designed and used for drug targeting. Albumin-ligand complexes with new properties can be made. The bioavailability of peptide-therapeutics can be prolonged by forming albumin fusions. In time, it will probably be possible to tailor useful albumins to specific types of patients.
Kragh-Hansen
Ulrich
U
Aarhus Universitet, Institut for Medicinsk Biokemi, Arhus C. ukh@biokemi.au.dk
D001682:Biological Availability; D050939:Gene Fusion; D006207:Half-Life; D006801:Humans; D016296:Mutagenesis; D011485:Protein Binding; D020033:Protein Isoforms / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D012709:Serum Albumin / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use
D020033:Protein Isoforms; D011994:Recombinant Proteins; D012709:Serum Albumin